Notícias Eagle Capital Growth Fund Inc - GRF | Ações American Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
AMEX
Eagle Capital Growth Fund Inc (GRF)
Eagle Capital Growth Fund Inc (GRF) Notícias

Eagle Capital Growth Fund Inc (GRF)

10,54

0,49

(4,88%)

Fechado 29 Novembro 6:00PM

Atrasado por 15 minutos

10,54

0,00

(0,00%)

Após o horário de negociação: 6:00PM

Atrasado por 15 minutos

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Form 4 - Statement of changes in beneficial ownership of securities

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form N-PX - Annual Report of proxy voting record of management investment companies

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Eagle Capital Growth

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições